Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 3 - Drugs for disorders of the metabolism
Patents for A61P 3 - Drugs for disorders of the metabolism (129,789)
12/2003
12/04/2003US20030225164 Carbocyclic amines such as 4-(3-(4-Phenylcyclohexylamino)-propyl)phenol, administered as N-Methyl-D-Aspartate (NMDA) receptor inhibitors, for prophylaxis of cardiovascular, brain or nervous system disorders
12/04/2003US20030225160 Esterified hydroxytyrosol; 2-(3,4-dihydroxyphenyl)ethyl acetate for example
12/04/2003US20030225158 Compounds that modulate PPAR activity and methods for their preparation
12/04/2003US20030225152 Such as 3-phenylaminomethylene-1,3-dihydroindol-2-one; use treating cancer, blood vessel proliferative disorders, fibrotic disorders, mesangial cell proliferative disorders and metabolic diseases
12/04/2003US20030225151 Pyrazole compositions useful as inhibitors of ERK
12/04/2003US20030225147 Inhibit activity of protein kinases; for tumor growth, angiogenesis, viral infection, autoimmune disease or neurodegenerative disorder
12/04/2003US20030225141 Thiazole derivatives
12/04/2003US20030225138 3-(2,6-Dichloro-4-pyrydyl)-5-(substituted or nonsubstitutedbenzyl)- 2,4-imidazolidinedione derivatives useful for the treatment of inflammatory diseases
12/04/2003US20030225128 For treating conditions such as erectile dysfunction, cardiovascular disorders, male or female sexual dysfunction, diabetes mellitus, and gastrointestinal disorders
12/04/2003US20030225117 Use of NAD(P)H oxidase inhibitors to increase cellular uptake of glucose and in the treatment and/or prevention of diseases caused by insulin resistance or diseases related thereto, such as type II diabetes
12/04/2003US20030225111 Use of a quinazoline derivative such as 1-(2,6-dichloro-phenyl)-3-(7-(3-morpholinopropoxy)quinazolin-4-yl) urea to produce an antiangiogenic and/or vascular permeability reducing effect
12/04/2003US20030225105 New linear cyclic ureas
12/04/2003US20030225102 Dipeptidyl peptidase inhibitors; heterocyclic amide and semicarbazide derivatives, e.g., (2-Cyano-1-(piperazine-2-yl)-carbonyl pyrrolidine bis-trifluoroacetate
12/04/2003US20030225097 Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor
12/04/2003US20030225083 Oxazole derivatives, such as 3-(4-(2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy)-2-(pyridin-2-ylmethoxy) -phenyl)-propionic acid
12/04/2003US20030225077 Naphthylamines used to chronic inflammatory diseases.
12/04/2003US20030225075 Novel pyrimidone derivatives
12/04/2003US20030225072 Opioid receptor active compounds
12/04/2003US20030225065 Use of 4-(1,4-diazepan-1-yl)- or 4-piperazin-1-yl-2-aminophenyl phenyl sulfones for treatment of disorders of the central nervous system.
12/04/2003US20030225061 Protease inhibitors
12/04/2003US20030225060 Acylated piperidine derivatives as melanocortin-4 receptor agonists
12/04/2003US20030225058 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity
12/04/2003US20030225057 3-Benzoazepine derivatives
12/04/2003US20030225056 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
12/04/2003US20030225051 Also estrogen phosphonates, thiophosphonates, sulphonates, sulphonamides, and N-acylsulfamates
12/04/2003US20030225038 Adenosine receptor antagonists and methods of making and using the same
12/04/2003US20030224983 Stimulation of beta cell proliferation
12/04/2003US20030224982 Therapeutic polypeptides, nucleic acids encoding same, and methods of use
12/04/2003US20030224973 Minimising body gain in insulin treatment
12/04/2003US20030224413 Comprises polynucleotides coding restriction fragment length polymorphism for use in identifying, characterizing and treatment of blood, respiratory, tumor and nervous system disorders
12/04/2003US20030224360 Interventions to mimic the effects of calorie restriction
12/04/2003US20030224348 Methods of screening for SCAP antagonists
12/04/2003US20030224347 Pharmaceutical compositions
12/04/2003US20030224014 Preparation and standardization of immunomodulatory peptide-linked glucans with verifiable oral absorbability from coriolus versicolor
12/04/2003US20030223992 G-protein coupled receptor ligands and methods
12/04/2003US20030223969 Method of modulating inflammatory response
12/04/2003CA2784937A1 Ccr9 inhibitors and methods of use thereof
12/04/2003CA2489145A1 Insulin-sensitizing agent
12/04/2003CA2487557A1 Modulators and inhibitors of fibroblast growth factor receptor 5 polypeptides and gene expression thereof
12/04/2003CA2487303A1 Assays for modulators of asparaginyl hydroxylase
12/04/2003CA2487269A1 Novel exendin agonist formulations and methods of administration thereof
12/04/2003CA2487167A1 Combination of a dpp iv inhibitor and a cardiovascular compound
12/04/2003CA2486966A1 Substituted quinazolinone compounds
12/04/2003CA2486962A1 Compounds
12/04/2003CA2486853A1 Bis-aromatic alkanols
12/04/2003CA2486821A1 1-thia-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof
12/04/2003CA2486716A1 Compositions and their uses for alleviating pain
12/04/2003CA2486665A1 Extraction of unmilled psyllium
12/04/2003CA2486651A1 Sulfone liver x-receptor modulators
12/04/2003CA2486644A1 Anilino liver x-receptor modulators
12/04/2003CA2486613A1 Chewable compositions containing a gel-forming extract of psyllium
12/04/2003CA2486187A1 Kinase inhibitors
12/04/2003CA2485984A1 Pharmaceutical combination of pde5 inhibitors with ace inhibitors
12/04/2003CA2485184A1 Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
12/04/2003CA2485166A1 Substituted pyrimidinone and pyridinone compounds
12/04/2003CA2484822A1 Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
12/04/2003CA2484274A1 Compositions and methods of use for a fibroblast growth factor
12/04/2003CA2480742A1 Tropane compounds
12/03/2003EP1367065A1 Acid soluble proteins from micellar casein
12/03/2003EP1367060A1 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
12/03/2003EP1367058A1 Tetrahydropyran derivatives
12/03/2003EP1366165A2 G-protein coupled receptors
12/03/2003EP1366164A1 Nucleic acid expressed in the hypothalamus or muscle tissue in obese animals
12/03/2003EP1366162A2 Putative proteins and nucleic acids encoding same
12/03/2003EP1366161A2 Interleukin-8 homologous polypeptides and therapeutic uses thereof
12/03/2003EP1366150A2 Use of protein histidine phosphatase
12/03/2003EP1366148A2 Differentiation of stem cells to pancreatic endocrine cells
12/03/2003EP1366079A2 Nuclear hormone receptor ligand binding domain
12/03/2003EP1366078A2 Ige receptor antagonists
12/03/2003EP1366059A2 Methods and compositions for modulating gluconeogenesis using pgc-1
12/03/2003EP1366052A2 Novel multi-ring organic compounds for regulating gut motility and food intake
12/03/2003EP1366036A2 Compounds having activity as inhibitors of cytochrome p450rai
12/03/2003EP1366033A1 Chemical compounds
12/03/2003EP1366030A2 Melanin concentrating hormone receptor ligands
12/03/2003EP1366024A2 Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
12/03/2003EP1366016A2 Process for the preparation of arylethanoldiamines useful as agonists of the beta-3-adrenoceptor
12/03/2003EP1366012A2 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
12/03/2003EP1366007A2 Compounds with high monoamine transporter affinity
12/03/2003EP1365806A2 Use of no acttivators for treatment and prevention of gastrointestinal disorders
12/03/2003EP1365800A2 Methods for using tetanus toxin for benificial purposes in animals (mammals)
12/03/2003EP1365798A2 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
12/03/2003EP1365785A2 Use of ciliary neurotrophic factor
12/03/2003EP1365779A1 Pharmaceutical or dietary composition containing a vegetable oil, in particular olive oil, and sitosterol
12/03/2003EP1365771A1 Method of treating certain eye diseases
12/03/2003EP1365762A1 Method for increasing leptin levels using nicotinic acid compounds
12/03/2003EP1365761A1 Therapeutic combination of amlodipine and benazepril
12/03/2003EP1365760A1 Preparations and use of an ah receptor ligand, 2-(1'h-indole-3'-carbonyl)-thiazole-4-carboxylic acid methyl ester
12/03/2003EP1365756A2 Method of treating the syndrome of type 2 diabetes in humans
12/03/2003EP1257555B1 Pyrimidine compounds and their use as modulators of chemokine receptor activity
12/03/2003EP1246634B1 Neurotoxins for treating pancreatic disorders
12/03/2003EP1150963B1 Substituted 4-amino-2-aryltetrahydroquinazolines, their preparation, their use and pharmaceutical compositions comprising them
12/03/2003EP1119557B1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
12/03/2003EP1027037B1 Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
12/03/2003EP1015437B1 Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
12/03/2003EP0821004B1 Peptides and remedy for bone diseases containing the same as active ingredient
12/03/2003CN1460105A 黄嘌呤磷酸二酯酶v抑制剂 Xanthine phosphodiesterase inhibitor v
12/03/2003CN1460102A Creatine salt having enhanced nutritional and therapeutic efficacy and compositions containing same
12/03/2003CN1460025A Immunomodulatory human MHC class Ôàí antigen-binding polypeptides
12/03/2003CN1459459A Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of rainbow conk
12/03/2003CN1459448A Preparation method of red sageroot total phenolic acid and its use
1 ... 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 ... 1298